The Food and Drug Administration (FDA) has approved Breo Ellipta (fluticasone furoate/vilanterol) for the once-daily treatment of asthma in patients aged 18 years and older. The approval of the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
WASHINGTON (AP) -- The Food and Drug Administration says it has approved a new once-a-day inhaler drug from GlaxoSmithKline for patients with chronic lung disease. The agency cleared the Breo Ellipta ...
Government health advisers say a once-a-day respiratory inhaler from GlaxoSmithKline appears safe and effective for adults with asthma, but not for adolescents. The Food and Drug Administration panel ...
BREO ELLIPTA (fluticasone furoate and vilanterol) Inhalation Powder Breo Ellipta (fluticasone furoate/vilanterol; GlaxoSmithKline and Theravance) has been made available for chronic obstructive ...
WASHINGTON (AP) — A panel of respiratory experts voted Wednesday in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravance for treating chronic lung disease. A majority of ...
At first blush, the pedestrian world of drug manufacturing and the high-speed environs of Formula One racing would seem to have little in common. But GlaxoSmithKline ...
LONDON—A large clinical trial run by GlaxoSmithKline PLCGSK1.12%increase; green up pointing triangle has failed to show that the company’s Breo Ellipta inhaler extends life in patients with chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results